论文部分内容阅读
恰那林(马来酸依那普利)是1980年由美国开发的一种特异性高、作用时间长、不含巯基的口服血管紧张素转换酶抑制剂(ACEI).我国于1982年由常州制药厂开始研制,于1994年由国家卫生部批准正式生产.本品适用于各期原发性高血压、肾血管性高血压及充血性心力衰竭.我们应用其治疗冠心病慢性充血性心力衰竭(CHF)24例,取得了满意的疗效,现分析报告如下.1 临床资料1.1 一般资料 冠心病CHF患者共24例,男14例,女10例;年龄48～82岁,平均60.4岁.其中4例并陈旧性心肌梗塞,8例并原发性高血压病.心衰病程1～14年.心功能分级(按NYHA分级标准)Ⅲ级6例,Ⅵ级18例.1.2 治疗方法 恰那林开始剂量每日5～10mg,分2次口服,根据疗效及血压水平逐渐增加剂量,直至疗效满意为止.但每日最大剂量不宜超过40mg,同时配以小
Calyaline (enalapril maleate) is a kind of oral angiotensin-converting enzyme inhibitor (ACEI) developed by the United States in 1980 with high specificity, long acting time and no sulfhydryl group.Our country was established in 1982 by Changzhou Pharmaceutical Factory began to develop, in 1994 by the National Ministry of Health approved the official production. This product is suitable for all stages of essential hypertension, renal vascular hypertension and congestive heart failure. We apply its treatment of coronary heart disease with chronic congestive heart (CHF) in 24 cases, and achieved satisfactory results, the following analysis reports are as follows.1 Clinical data 1.1 General information of coronary heart disease CHF patients were 24 cases, 14 males and 10 females; aged 48 to 82 years, mean 60.4 years old. 4 cases with old myocardial infarction, 8 cases with primary hypertension.Fat failure ranged from 1 to 14 years.Cardiac function grading (according to the NYHA grading standards) in grade 6 in 6 cases, grade Ⅵ in 18 cases .1.2 treatment method just The forest began daily dose of 5 ~ 10mg, 2 times orally, according to the efficacy and blood pressure levels gradually increase the dose until the results are satisfactory, but the daily maximum dose should not exceed 40mg, accompanied by small